^
    Back
    Association details:
    Biomarker:LYPD3 expression
    Cancer:Non Small Cell Lung Cancer
    Drug:lupartumab amadotin (BAY1129980) (Microtubule inhibitor, C4.4a-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Mol Cancer Ther
    Title:

    Preclinical Antitumor Efficacy of BAY 1129980—a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody–Drug Conjugate for the Treatment of Non–Small Cell Lung Cancer

    Excerpt:
    We have generated BAY 1129980 (C4.4A-ADC)...C4.4A expression level correlated with in vivo efficacy, the most responsive being the models with C4.4A expression in over 50% of the cells.
    DOI:
    10.1158/1535-7163.MCT-16-0474